

1 SUPPLEMENTARY TEXT S1

2 Strain construction

3 All *C. neoformans* strains used were in the serotype A KN99 α background. For strain
4 construction, we used a split-marker strategy (1) with biolistic transformation, selected
5 candidates by patterns of drug resistance, and confirmed all candidate transformants by
6 PCR and whole genome sequencing. We first generated two *ysp2* Δ deletion strains by
7 replacing *YSP2* with either a G418 (2) or NAT resistance marker (3). To complement
8 these mutants at the native site, we replaced the G418 or NAT coding sequence with the
9 *YSP2* coding sequence, preceded by a NAT or G418 resistance marker, respectively. To
10 endogenously tag *YSP2*, we used a tagging module consisting of codon-optimized
11 mNeonGreen, a tandem Calmodulin Binding Peptide-2X FLAG Tag, and a NAT
12 resistance marker.

13 To endogenously tag Pma1, we used a CRISPR-Cas9 strategy to tag the C-terminus of
14 Pma1 (*CNAG_06400*) with an mNeonGreen tagging module as described above in
15 tandem with a G418 marker (4).

16 BMDM Preparation

17 For bone marrow-derived macrophages (BMDMs), we isolated bone marrow from
18 C57BL/6 mouse femurs and expanded the cellular population by growth in BMDM
19 medium (RPMI supplemented with 10% heat-inactivated FBS and 20% L cell supernatant)
20 for seven days. Macrophages were isolated using anti-F4/80 conjugated biotin and anti-
21 biotin magnetic microbeads.

22 Microscopy

23 For imaging, fungal strains were grown as in the main text and resuspended at 10^7
24 cells/ml for staining with Lucifer Yellow (200 μ g/ml, 30 min, RT), calcofluor white, (100
25 μ g/ml, 15 min, RT), filipin (5 μ g/ml 10 min, RT), amphotericin B-Cy5 (10 μ M, 45 min, 37°C),
26 or Nile Red (0.0005%, 15 min, RT) (5–7). For capsule imaging, cells were resuspended
27 in 600 μ l PBS and mixed with 300 μ l India Ink or stained (30 min, RT) with 50 μ g/ml of
28 anticapsular monoclonal antibody 302 conjugated to Alexa Fluor 488 (Molecular Probes).

29 For electron microscopy, cells were grown as described above and fixed in 2.5%
30 glutaraldehyde (Ted Pella Inc., Redding, CA) in 0.1 M sodium cacodylate buffer for 1 h at
31 room temperature and then overnight at 4°C. Samples were washed in sodium cacodylate
32 buffer and postfixed in 1% osmium tetroxide (Ted Pella Inc.) for 1 h at room temperature
33 before dehydration by successive 30 min incubations in water–ethanol mixtures with
34 increasing ethanol concentrations. The ethanol-substituted samples were then
35 substituted in propylene oxide (twice for 30 min each) and infiltrated and embedded in
36 Eponate 12 resin (Ted Pella, Redding, CA). Blocks were polymerized overnight at 65°C.
37 Ultrathin sections of 95 nm were cut with a Leica Ultracut UCT ultramicrotome (Leica
38 Microsystems, Bannockburn, IL), stained with uranyl acetate and lead citrate, and viewed
39 on a JEOL 1200 EX transmission electron microscope (JEOL USA Inc., Peabody, MA)
40 equipped with an AMT 8-megapixel digital camera and AMT Image Capture Engine V602
41 software (Advanced Microscopy Techniques, Woburn, MA).

Sterol Analysis

Lipid extraction was performed as previously described with slight modifications (8). Briefly, 5×10^8 cells were washed twice in sterile water and resuspended in 1 ml chloroform: 0.8 ml dH₂O: 2 ml methanol. Samples were vortexed, sonicated (Fisher Scientific Sonic Dismembrator Model 300; 40% power for 30 s) three times at intervals of 30 s, and incubated at 60°C for 15 min. This process was repeated, cell debris was removed by centrifugation, and the supernatant fraction was evaporated and stored at -20°C.

For TLC analysis, lipid extracts were resuspended in 100 µl of chloroform-methanol (2:1), spotted (20 µl) on silica plates along with standards (5 µg ergosterol and 10 µg of cholesteryl oleate), and the plates were developed in petroleum ether-diethyl ether-acetic acid (80:20:1 [vol/vol/vol]) (9). Total lipids were visualized by treatment with sterol spray (50% ethanol in water, 3.2% H₂SO₄, and 0.5% MnCl₂) followed by 30 minutes of charring at 120°C (10). Densitometry was performed using ImageJ software.

References

1. Fu J, Hettler E, Wickes BL. 2006. Split marker transformation increases homologous integration frequency in *Cryptococcus neoformans*. Fungal Genetics and Biology 43:200–212.
2. Hua J, Meyer JD, Lodge JK. 2000. Development of Positive Selectable Markers for the Fungal Pathogen *Cryptococcus neoformans*. Clin Diagn Lab Immunol 7:125–128.

- 63 3. McDade HC, Cox GM. 2001. A new dominant selectable marker for use in
64 *Cryptococcus neoformans*. Medical Mycology 39:151–154.

- 65 4. Huang MY, Joshi MB, Boucher MJ, Lee S, Loza LC, Gaylord EA, Doering TL,
66 Madhani HD. 2022. Short homology-directed repair using optimized Cas9 in the
67 pathogen *Cryptococcus neoformans* enables rapid gene deletion and tagging.
68 Genetics 220:iyab180.

- 69 5. Thoms S, Debelyy MO, Connerth M, Daum G, Erdmann R. 2011. The Putative
70 *Saccharomyces cerevisiae* Hydrolase Ldh1p Is Localized to Lipid Droplets.
71 Eukaryotic Cell 10:770–775.

- 72 6. Nolan SJ, Fu MS, Coppens I, Casadevall A. 2017. Lipids Affect the *Cryptococcus*
73 *neoformans*-Macrophage Interaction and Promote Nonlytic Exocytosis. Infect Immun
74 85:e00564-17.

- 75 7. Kohlwein SD, Veenhuis M, van der Klei IJ. 2013. Lipid Droplets and Peroxisomes:
76 Key Players in Cellular Lipid Homeostasis or A Matter of Fat—Store 'em Up or
77 Burn 'em Down. Genetics 193:1–50.

- 78 8. Singh A, MacKenzie A, Girnun G, Del Poeta M. 2017. Analysis of sphingolipids,
79 sterols, and phospholipids in human pathogenic *Cryptococcus* strains. J Lipid Res
80 58:2017–2036.

- 81 9. Siafakas AR, Wright LC, Sorrell TC, Djordjevic JT. 2006. Lipid Rafts in *Cryptococcus*
82 *neoformans* Concentrate the Virulence Determinants Phospholipase B1 and Cu/Zn
83 Superoxide Dismutase. Eukaryot Cell 5:488–498.

- 84 10. Knittelfelder OL, Kohlwein SD. 2017. Thin-Layer Chromatography to Separate
85 Phospholipids and Neutral Lipids from Yeast. Cold Spring Harb Protoc
86 2017:pdb.prot085456.

87